Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer

PURPOSE: Combination of anthracyclines with trastuzumab is hampered by cardiotoxicity. Pegylated liposomal doxorubicin and lapatinib could represent a safer alternative to combination therapy. METHODS: In this phase Ib study with 3 + 3 dose escalation design, patients with HER2-positive advanced bre...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Chemother Pharmacol
Glavni autori: Rocca, Andrea, Cecconetto, Lorenzo, Passardi, Alessandro, Melegari, Elisabetta, Andreis, Daniele, Monti, Manuela, Maltoni, Roberta, Sarti, Samanta, Pietri, Elisabetta, Schirone, Alessio, Fabbri, Francesco, Donati, Caterina, Nanni, Oriana, Fedeli, Anna, Faedi, Marina, Amadori, Dino
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2017
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5403877/
https://ncbi.nlm.nih.gov/pubmed/28341957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3279-8
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items